Irritable Bowel Syndrome (IBS)
This care pathway can be used to guide primary care providers in the management of patients with irritable bowel syndrome (IBS). This care pathway was developed by the specialists at the GI Motility Clinic at the Toronto Western Hospital and follows the Canadian Association of Gastroenterology (CAG) guideline for the management of irritable bowel syndrome as defined by the Rome IV criteria.
Summary of IBS
Irritable bowel syndrome (IBS) is one of the most common disorders of gut-brain interaction (DGBI). It is characterized by recurrent abdominal pain associated with bowel movements and/or a change in bowel habits.
​
It is estimated that IBS affects about 10% of the global population. In Canada, there is an estimated prevalence rate of 12%. Women tend to be affected approximately two times more often than men.
​
Abdominal pain must be present, and the absence of abdominal pain excludes IBS diagnosis. Abdominal pain can be anywhere throughout the abdomen but is common in the lower abdominal area and is typically intermittent. This pain can change with bowel movements (either improves or worsens) and/or is associated with a change in stool frequency and/or form.

Diagnosing IBS
An IBS diagnosis requires a thoughtful approach, limited diagnostic tests, and careful follow-up.
​
Diagnosis is based on:
-
Clinical history
-
Physical examination
-
Minimal investigations

Rome IV Criteria
for IBS
Recurrent abdominal pain occurring at least 1/week in the last 3 months & associated with 2 or more of the following criteria:
​
-
Related to defecation
-
Associated with change in frequency of stool
-
Associated with a change in stool form
​
Criteria fulfilled for the last 3 months with symptom onset at least 6 months before diagnosis
IBS is classified into four subtypes according to the stool form. Subtyping should be based on the patient’s reported predominant form on days with abnormal bowel movements and when they are not taking medication that can affect stool form (e.g. laxatives)
The Bristol stool form scale is a valuable tool for patients to identify their typical stool form and determine the patient’s IBS subtype. It is validated for the words only. Ask patients to read, if possible, the descriptions next to the picture and not just look at the picture when describing their stool form.
Patients whose bowel habits cannot be accurately categorized into 1 of the three groups are considered IBS unclassified subtype (IBS-U).
The patient should be encouraged to keep a 14-day stool and diet diary (appendix 1) using BSFS to document stool consistency.

CONSTIPATION SUBTYPE:
More than 25% of bowel movements with Bristol stool form types 1 or 2 and less than 25% of bowel movements for Bristol stool form types 6 or 7. Alternatively, patient reports that abnormal bowel movements are usually constipation (Bristol forms 1 to 2).
DIARRHEA SUBTYPE:
More than 25% of bowel movements with Bristol stool form types 6 or 7 and less than 25% of bowel movements with Bristol stool form 1 or 2. Alternatively, patient reports abnormal bowel movements are usually diarrhea (Bristol forms 6 to 7).
MIXED SUBTYPE:
More than 25% of bowel movements with Bristol stool forms type 1 or 2 and more than 25% of bowel movements with Bristol stool form types 6 or 7. Alternatively, the patient reports that abnormal bowel movements are usually both constipation and diarrhea.
UNCLASSIFIED SUBTYPE:
Patients who meet diagnostic criteria for IBS but whose bowel habits cannot be accurately categorized into 1 of the 3 groups above should be categorized as having IBS classified.
PRIMARY CARE CHECKLIST
-
Patient meets Rome IV criteria for IBS
-
Absence of alarm features:
-
Anemia, iron deficiency, GI bleeding
-
acute or unintentional weight loss
-
recent change in bowel habits, nocturnal or progressive symptoms
-
onset after the age of 50
-
FIT positive if done for screening purposes
-
abnormality on physical exam
-
-
Negative serological testing for celiac disease (anti-tTG IgA)​
-
No family history of inflammatory bowel disease, colorectal cancer, or celiac disease
DIAGNOSTIC ALGORITHM FOR IBS
Consider referral to GI
YES
Suspected IBS
Alarm Features?
NO
CBC, ferritin, celiac screening
Establish diagnosis of IBS
If abnormal results, investigate and treat as appropriate
Meets Rome IV criteria for IBS
GENERAL PRINCIPLES OF IBS TREATMENT
-
patient counselling and reassurance
-
trial of soluble fiber
-
if pain is the main feature, trial of peppermint oil or antisposmadics
-
stress reduction
-
treat sleep disturbances or psychological issues
Specific investigations and treatment​ option based on IBS subtype
Diarrhea
IBS-D
FURTHER INVESTIGATIONS:
Stool cultures (C. difficile, C&S, O&P); electrolytes, albumin
Negative results
TREATMENT OPTIONS:
-
soluble fiber
-
probiotics
-
low-dose TCA
-
SSRI or SNRI*
-
Eluxadoline
-
Rifaximin
-
cognitive behavioural therapy
-
hypnotherapy
Constipation
IBS-C
FURTHER INVESTIGATIONS:
TSH, electrolytes, calcium
Negative results
TREATMENT OPTIONS:
-
soluble fiber
-
osmotic laxatives
-
Linaclotide
-
Plecanatide
-
Tenapenor
-
low-dose TCA
-
SSRI or SNRI*
-
cognitive behavioural therapy
-
hyponotherapy
Mixed
IBS-M
FURTHER INVESTIGATIONS:
Stool cultures (C. difficile, C&S, O&P); electrolytes, albumin, calcium, TSH
Negative results
-
probiotics
-
low-dose TCA
-
SSRI or SNRI*
-
cognitive behavioural therapy
-
hypnotherapy
TREATMENT OPTIONS:
*Treatment choice should depend on patient's symptoms and comorbities
EXPLANATION OF ALGORITHM
PHYSICAL & HISTORY ASSESSMENT
A complete history and relevant examination are required when diagnosing IBS, with limited use of diagnostic tests. It is a diagnosis based on clinical symptoms. Exclude alarm features as listed above. The presence of alarm features should prompt consideration of a referral to a Gastroenterologist.
INVESTIGATIONS
A CBC should be performed in all patients presenting with IBS symptoms to rule out anemia that may require further investigation.
Symptoms of celiac disease often overlap with IBS, particularly diarrhea and bloating. Celiac serology is recommended and can be performed as anti-tTG IgA. This test should always be done simultaneously with a serum IgA level; IgA deficiency can cause false-negative anti-tTG tests.
GENERAL PRINCIPLES OF IBS TREATMENT
Developing a therapeutic relationship with the patient at the time of diagnosis is the foundation of effective long-term management. It is essential to provide reassurance by acknowledging the patient’s symptoms and offering a continued assessment of treatment response. It is helpful to discuss what factors may have contributed to the individual patient’s IBS and how those factors may be treatment targets. Discussion of the role of the gut-brain axis can help frame a patient’s understanding of their illness and treatment plan. It is important to set realistic treatment goals in the management of IBS.
All patients with IBS will benefit from lifestyle and dietary modifications. If available, patients should be connected with resources for dietary modification, exercise (yoga has shown to be beneficial), stress reduction strategies, and psychological counselling, if appropriate.
DIETARY
A trial of soluble fibre (e.g. psyllium, guar gum) and not insoluble fibre (e.g. wheat) may be helpful. It has been shown to bulk stool formation, alter the production of gas from fermented products, and change the composition of the gut microbiome.
​
The low FODMAP diet has been shown to be effective in improving overall IBS symptoms, bloating, and stool form (in IBS-D only). If available, refer the patient to a Registered Dietician to trial the low FODMAP diet. If a Registered Dietician is not available, the patient can be directed to access the resources listed below. Emphasize to the patient that this is not a lifelong diet. Instead, it is used to determine trigger foods that may contribute to symptoms. The patient can trial the low FODMAP diet for 4 to 6 weeks to determine if it reduces IBS symptoms. The patient then must move on to the reintroduction phase. During the reintroduction phase, the patient should keep a food diary to track restarted food items and their symptoms (Appendix 2). The patient should reintroduce one food item over three days to determine if it causes symptoms. When the patient can identify trigger foods, reassure the patient they do not have to completely stop eating the food item (especially if it is something they enjoy eating), but simply be more mindful of its effects on their GI symptoms and reduce its intake. Please note that this type of elimination may not be appropriate for all patients with IBS.
​
​
OVER-THE-COUNTER OPTIONS
There are effective over-the-counter options for managing abdominal pain. Peppermint oil in delayed-release capsules has shown to alleviate symptoms of abdominal pain, bloating, and a sense of urgency. Ingesting pure peppermint oil has shown to increase acid reflux symptoms. The encapsulated form is released in the small bowel to reduce this risk.
Antispasmodic medications have also proven to help alleviate abdominal pain and cramps.
Probiotics are another option as there is growing research regarding the relationship between IBS and the gut microbiome. The two commonly researched strains for IBS are lactobacillus and bifidobacterium. Overall, probiotics were statistically superior to placebo in reducing abdominal pain, bloating, and flatulence. As the evidence for probiotics is still emerging, patients should be advised to limit their trial period to one month. If there is no effect on their IBS symptoms, treatment should be discontinued.
PSYCHOLOGICAL
It is important to assess any stressors that may trigger IBS symptoms. During the assessment, inquire if the patient’s IBS symptoms started within 6 to 12 months of a stressful event. Childhood trauma has also been associated with IBS and should be addressed if appropriate. A referral to a psychologist specializing in cognitive behavioural therapy (CBT) or gut-directed hypnotherapy has shown to be effective in teaching patients relaxation techniques to manage their symptoms.
PHARMACOLOGICAL MANAGEMENT
Pharmacological options can complement conservative therapies to optimize IBS symptom control.
The use of neuromodulators/antidepressants has been shown to improve IBS symptoms. Other pharmacological options can be considered to address symptoms but may not improve overall IBS symptoms. Emphasize to patients that symptom control is based on multiple variables (lifestyle, diet modification, medication, etc.) and that treatment is individualized.
NEUROMODULATOR - TRICYCLIC ANTIDEPRESSANTS
Target symptoms: abdominal pain & bloating
Examples: amitriptyline & desipramine
Recommended dose: Start 10 mg every night. Can titrate to a max dose of 50 mg daily
Patient education: The patient may feel effects in 2 to 3 weeks. Full effect is expected in about 8 to 12 weeks.
Side effects: drowsiness/fatigue, constipation, increased appetite, weight gain, dry mouth, dry eyes
​
NEUROMODULATOR - SSRI
Target symptom: abdominal pain
Example: escitalopram
Recommended dose: start 20 mg daily
Patient education: monitor mood during therapy. Assess for serotonin syndrome
Side effects: drowsiness, sleep disturbance, tremors, anorexia, diarrhea, serotnin syndrome
NHE3 INHIBITOR
Target symptoms: constipation, abdominal pain, bloating
Example: Tenapanor (Ibsrela)
Recommended dose: 50 mg BID
Patient education: Take immediately before first meal of the day and immediately before dinner. Lesser diarrheal side effects compared to linaclotide.
Side effects: diarrhea
NEUROMODULATOR - SNRI
Target symptoms: abdominal pain and bloating
Example: duloxetine
Recommended dose: Start 30 mg daily. Can titrate to a max dose of 60 mg daily
Patient education: The patient may feel effects in 2-3 weeks. Full effect is expected in about 8-12 weeks. May also be helpful for patients with fibromyalgia, chronic pelvic pain
Side effects: disturbed sleep, agitation, increased sweating, decreased appetite, constipation, nausea
SECRETAGOGUES
Target symptoms: constipation, abdominal pain
Examples: Linaclotide (Constella), Plecanatide (Trulance)
Recommended dose:
Linaclotide - start 290 mcg daily and adjust based on patient's tolerance
Plecanatide - start 3 mg daily
Patient education:
Linaclotide - peak effect 6 to 9 weeks. Take 30 mins before the first meal to prevent diarrhea
Plecanatide - lesser diarrheal side effects. Can be taken with or without food.
Side effects: diarrhea
ANTIBIOTIC
Target symptoms: diarrhea, abdominal pain, bloating
Example: Rifaxamin (Zaxine)
Recommended dose: 550 mg TID for 14 days. 80 to 90% concentrated in the gut. If there is recurrence of symptoms, may treat up to an additional 2 times
Patient education: Do no stop medication if diarrhea worsens. Complete the duration of treatment even if symptoms improve
Side effects: C. difficile associated diarrhea, dizziness
